Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The latest announcement is out from Lexicon Pharmaceuticals ( (LXRX) ).
On November 6, 2025, Lexicon Pharmaceuticals filed a prospectus supplement related to its Open Market Sale Agreement with Jefferies LLC, allowing the sale of up to $75 million in common stock. The filing inadvertently stated that Ernst & Young LLP audited the company’s internal controls, which is not required for Lexicon as a smaller reporting company, highlighting a correction in the documentation.
The most recent analyst rating on (LXRX) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Lexicon Pharmaceuticals stock, see the LXRX Stock Forecast page.
Spark’s Take on LXRX Stock
According to Spark, TipRanks’ AI Analyst, LXRX is a Neutral.
Lexicon Pharmaceuticals shows strong revenue growth and promising R&D advancements, but profitability and cash flow challenges weigh heavily on its financial performance. The technical indicators suggest bearish momentum, while the valuation reflects high risk due to ongoing losses. The earnings call provides a cautiously optimistic outlook, highlighting strategic progress and partnerships. Overall, the stock presents potential growth opportunities but with significant risks.
To see Spark’s full report on LXRX stock, click here.
More about Lexicon Pharmaceuticals
Lexicon Pharmaceuticals, Inc. is a Delaware-based company operating in the pharmaceutical industry, focusing on the development and commercialization of treatments for human diseases.
Average Trading Volume: 2,299,335
Technical Sentiment Signal: Sell
Current Market Cap: $454.2M
For a thorough assessment of LXRX stock, go to TipRanks’ Stock Analysis page.